Impact of age and antibody type on progression from single to multiple autoantibodies in type 1 diabetes relatives

Journal of Clinical Endocrinology and Metabolism

Volumn 102, Issue 8, 2017, Pages 2881-2886

  Bosi, Emanuele ^a   Boulware, David C ^b   Becker, Dorothy J ^c   Buckner, Jane H ^d   Geyer, Susan ^b   Gottlieb, Peter A ^e   Henderson, Courtney ^b   Kinderman, Amanda ^b   Sosenko, Jay M ^f   Steck, Andrea K ^e   Bingley, Polly J ^g  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MIAMI   (United States)

^g UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE DECARBOXYLASE ANTIBODY; HLA DQB1 ANTIGEN; INSULIN ANTIBODY; INSULINOMA ASSOCIATED ANTIGEN 2 ANTIBODY; PANCREAS ISLET CELL ANTIBODY; UNCLASSIFIED DRUG; ZINC TRANSPORTER 8 ANTIBODY; AUTOANTIBODY; CATION TRANSPORT PROTEIN; GLUTAMATE DECARBOXYLASE; INSULIN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; SLC30A8 PROTEIN, HUMAN;

ADOLESCENT; AGE DISTRIBUTION; ANTIBODY DETECTION; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; FIRST-DEGREE RELATIVE; GLUCOSE TOLERANCE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SECOND-DEGREE RELATIVE; SURVIVAL TIME; THIRD-DEGREE RELATIVE; ADULT; AGE; DISEASE COURSE; FAMILY; FOLLOW UP; GLUCOSE TOLERANCE TEST; IMMUNOLOGY; RADIOIMMUNOASSAY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AUTOANTIBODIES; CATION TRANSPORT PROTEINS; CHILD; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FAMILY; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; GLUTAMATE DECARBOXYLASE; HUMANS; INSULIN; MALE; RADIOIMMUNOASSAY; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 8; YOUNG ADULT;

EID: 85026923570     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2017-00569     Document Type: Article

References (28)

1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69-82.
2. Bonifacio E. Predicting type 1 diabetes using biomarkers. Diabetes Care. 2015;38(6):989-996.
3. Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974.
4. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C, Ilonen J, Veijola R, Knip M, Bonifacio E, Eisenbarth GS. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473-2479.
5. Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, Yu L, Palmer JP, Schatz D, Eisenbarth G; Diabetes Prevention Trial-Type 1 Study Group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care. 2009;32(12):2269-2274.
6. Ziegler AG, Bonifacio E; BABYDIAB-BABYDIET Study Group. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia. 2012;55(7):1937-1943.
7. Steck AK, Johnson K, Barriga KJ, Miao D, Yu L, Hutton JC, Eisenbarth GS, Rewers MJ. Age of islet autoantibody appearance and mean levels of insulin, but notGADor IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diabetes Care. 2011;34(6):1397-1399.
8. Parikka V, Näntö-Salonen K, Saarinen M, Simell T, Ilonen J, Hyöty H, Veijola R, Knip M, Simell O. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia. 2012;55(7): 1926-1936.
9. Steck AK, Vehik K, Bonifacio E, Lernmark A, Ziegler AG, Hagopian WA, She J, Simell O, Akolkar B, Krischer J, Schatz D, Rewers MJ; TEDDY Study Group. Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). Diabetes Care. 2015;38(5):808-813.
10. Krischer JP, Lynch KF, Schatz DA, Ilonen J, Lernmark Å, Hagopian WA, Rewers MJ, She JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Bonifacio E; TEDDY Study Group. The 6 year incidence of diabetes-associated autoantibodies in genetically atrisk children: the TEDDY study. Diabetologia. 2015;58(5): 980-987.
11. Achenbach P, Hummel M, Thümer L, Boerschmann H, Höfelmann D, Ziegler AG. Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children. Diabetologia. 2013;56(7):1615-1622.
12. Chmiel R, Giannopoulou EZ, Winkler C, Achenbach P, Ziegler AG, Bonifacio E. Progression from single to multiple islet autoantibodies often occurs soon after seroconversion: implications for early screening. Diabetologia. 2015;58(2):411-413.
13. Steck AK, Dong F, Waugh K, Frohnert BI, Yu L, Norris JM, Rewers MJ. Predictors of slow progression to diabetes in children with multiple islet autoantibodies. J Autoimmun. 2016;72: 113-117.
14. Mahon JL, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS; TrialNet Natural History Committee; Type 1 Diabetes TrialNet Study Group. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes. 2009; 10(2):97-104.
15. Vehik K, Beam CA, Mahon JL, Schatz DA, Haller MJ, Sosenko JM, Skyler JS, Krischer JP; TrialNet Natural History Study Group. Development of autoantibodies in the TrialNet Natural History Study. Diabetes Care. 2011;34(9):1897-1901.
16. Bingley PJ, Boulware DC, Krischer JP; Type 1 Diabetes TrialNet Study Group. The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia. 2016;59(3):542-549.
17. Xu P, Krischer JP; Type 1 Diabetes TrialNet Study Group. Prognostic classification factors associated with development of multiple autoantibodies, dysglycemia, and type 1 diabetes-a recursive partitioning analysis. Diabetes Care. 2016;39(6):1036-1044.
18. Yu L, Rewers M, Gianani R, Kawasaki E, Zhang Y, Verge C, Chase P, Klingensmith G, Erlich H, Norris J, Eisenbarth GS. Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab. 1996;81(12):4264-4267.
19. Bonifacio E, Yu L, Williams AK, Eisenbarth GS, Bingley PJ, Marcovina SM, Adler K, Ziegler AG, Mueller PW, Schatz DA, Krischer JP, Steffes MW, Akolkar B. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab. 2010;95(7):3360-3367.
20. Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL; Type 1 Diabetes TrialNet Study Group. Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care. 2012;35(6):1213-1218.
21. Ciampi IA, Thiffault J. Recursive partition and amalgamation (RECPAM) for censored survival data: criteria for tree selection. Statistical Software Newsletter. 1988;14:78-81.
22. Gordon L, Olshen RA. Tree-structured survival analysis. Cancer Treat Rep. 1985;69(10):1065-1069.
23. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and Regression Trees. Belmont, CA: Wadsworth International Group; 1984.
24. Meah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P, Evans-Molina C; Type 1 Diabetes TrialNet Study Group. The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants. Diabetologia. 2016;59(6):1186-1195.
25. Richter W, Seissler J, Northemann W, Wolfahrt S, Meinck HM, Scherbaum WA. Cytoplasmic islet cell antibodies recognize distinct islet antigens in IDDM but not in stiff man syndrome. Diabetes. 1993;42(11):1642-1648.
26. Bonifacio E, Lampasona V, Genovese S, Ferrari M, Bosi E. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J Immunol. 1995;155(11): 5419-5426.
27. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464(7293): 1293-1300.
28. Skyler JS. Prevention and reversal of type 1 diabetes-past challenges and future opportunities. Diabetes Care. 2015;38(6):997-1007.